kostya 75 mikrogramov/20 mikrogramov obložene tablete
accord healthcare - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
kostya 75 mikrogramov/20 mikrogramov obložene tablete
accord healthcare - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
ciprinol 100 mg/50 ml raztopina za infundiranje
krka, d.d., novo mesto - ciprofloksacin - raztopina za infundiranje - ciprofloksacin 2 mg / 1 ml - ciprofloksacin
ciprinol 200 mg/100 ml raztopina za infundiranje
krka, d.d., novo mesto - ciprofloksacin - raztopina za infundiranje - ciprofloksacin 2 mg / 1 ml - ciprofloksacin
zulfija 75 mikrogramov/30 mikrogramov obložene tablete
b. braun melsungen ag - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
zulfija 75 mikrogramov/30 mikrogramov obložene tablete
b. braun melsungen ag - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
zulfija 75 mikrogramov/30 mikrogramov obložene tablete
gedeon richter plc. - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol
dienille 2 mg/0,03 mg filmsko obložene tablete
exeltis magyarország gyógyszerkereskedelmi kft. - dienogest, etinilestradiol - filmsko obložena tableta - dienogest 2 mg / 1 tableta; etinilestradiol 0,03 mg / 1 tableta - progestogeni in estrogeni, enofazna zdravila
mekinist
novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 in 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib v kombinaciji z dabrafenib je indiciran za zdravljenje odraslih bolnikov z napredovalim non-small cell lung cancer z braf v600 mutacija.
advocin 180 - np - prenos